1129-178.111111 US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 11, 2003.

Gregory C. Houghton

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: George W. Muller, et al.

Serial No.: 10/622,618

Group Art Unit: Unknown

Filed: July 17, 2003

Examiner: Unknown

Title: Novel Immunotherapeutic Agents

Information Disclosure Statement

Commissioner for Patents Washington, DC 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant hereby brings to the attention of the United States Patent and Trademark Office the following documents of which Applicant has been made aware. The documents are listed on the attached PTO Form 1449. Copies of the documents are enclosed.

Applicant submits that this Information Disclosure Statement is submitted within six months of the filing date.

It is requested that the references be considered by the Examiner and be made of record as part of the available prior art under 37 C.F.R. § 1.104.

Respectfully submitted,

Gregory (Houghton

Reg. No. 47,666

Attorney for Applicant

MATHEWS, COLLINS, SHEPHERD & McKAY, P.A. 100 Thanet Circle, Suite 306 Princeton, NJ 08540 (609) 924-8555 - Telephone

(609) 924-3036 - Facsimile

1129-178.111111 US 10/622,618 INFORMATION DISCLOSURE CITATION Applicant(s) George W. Muller, et al. heets if necessary) Filing Date Group Art Unit **TBD** July 17, 2003 U.S. PATENT DOCUMENTS EXAMINER FILING DATE SUBCLASS CLASS NUMBER DATE NAME INITIAL IF APPROPRIATE Belanger, et al. 08/04/1992 5,135,940 FOREIGN PATENT DOCUMENTS Translation COUNTRY CLASS SUBCLASS REF DOCUMENT NUMBER DATE YES NO 07/11/1969 JP 44-26659 35 25 623 A1 01/22/1987 DE 10/31/1990 EP 0 395 446 A3 01/05/1994 42 20 983 A1 DE 94/14742 07/07/1994 wo OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R.W. Guthrie, et al., "Pentadienyl Carboxamide Derivatives as Antagonists of Platelet-Activating Factor", Journal of Medicinal Chemistry, Vol. 32, No. 8, Pages 1820-1835 (1989) Chem. SQ 8924.503 A. Shigehiro, et al., "Beta-Acrylcinnamitriles", Chemical Abstracts, Vol. 72 (5), (1970), Abstract 21510t EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Docket Number (Optional)

Form PTO-A820 (also form PTO-1449)

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

Application Number

INFORMATION DISCLOSURE CITATION (Use several structs if necessary)				1129-178.111111 US SERIAL NO. 10/622,618					
	∠ U 5 € seve	ral/shipets if neces	George W. Muller FILING		GROUP		= =		
	10 3	Mrs 2			July 17, 2			TBD	
	AUG	**************************************		S. PATEN	T DOCUMENTS				
*EXAMINER INITIAL	3000	NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
								<u> </u>	
			+	+			+	-	
				 					
							1		
				 			-	 	
			,	 				 	
			FORE	EIGN PATE	ENT DOCUMENTS	1			
	росим	MENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS		SLATION
	74/04800		07/07/1994	wo				YES	NO
	94/20455		09/15/1994	wo				1	
	96/20926		07/11/1996	wo				1	
	96/21435		07/18/1996	wo				1	
	-	OTHER DOCUME	NTS (Includin	ig Author	r, Title, Date, Pertine	ent Pages, Etc.)		
	Erikson Charal 1973, p	a, M., et al., "Gas kterierung von L pp. 127-140 comp	schromatographi igninen durch Mo ounds 40-46, p. 1	sche Anal ethylierun 34 (not tr	lye von Liginoxydation ng und oxydativen Abb anslated)	isprodukten.VII. Dau", ACTA Chei	Ein verbesserte mica Scandina	es Verfahre vica, Vol. 2	en zur :7 (1),
	Zarubi Dev., V	Zarubin, M.Y., et al., "Acid-base reactions to lignin with strong acids", Chemical Abstracts, Vol. 83 (14), 1975, Abs. Khin & Dev., Vol. 3 (1975) 117388n.							s. Khin &
EXAMINER					DATE CONSIDERED				
EXAMINER:	· Initial if reference (considered wheth	or or not citation is	in conform	nance with MPEP 609; D	line through o			-
onsidered. I	Include copy of this	form with next cor	mmunication to apr	plicant.	ance with MPEF 603, D	raw line through ci	tation if not in co	onformance	and not

Form PTO-A820 (also form PTO-1449)

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

				ATTY DOCKET NO. SERIAL NO. 1129-178.111111 US 10/622.618					
INFORMATIONALIS CLOSURE CITATION Q (Use several sects if necessary)							10/	/622,618	
	Q(Use se	everal spects if necess	ary)	4	George W. Muller, et a		250110		1-0-1-1
	10 0	3 700			July 17, 2003		GROUP	TBD	
		- Ala	U.S.	. PATENT	DOCUMENTS				
*EXAMINER INITIAL	1000	CUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
						1		IF ALL ING.	RIATE
			-						
			<u> </u>						
		Ţ							
						 			
									
-+			-						
			<u> </u>						
	<u> </u>								
							†		
						1			
							<u> </u>		
			FOREIG	3N PATEN	NT DOCUMENTS				
	DOC	CUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS		SLATION
	- 3 ()							YES	NO
								<u> </u>	
	_							I!	
									
									L
		OTHER DOCUMEN			Title, Date, Pertinent F				
	Man	Mamadzhanov, A., et al., "Condensation of pyrocathecol and its methyl ethers with alpha-phenylbenzyl alcohols in the presense of polyphosphoric acid", Chemical Abstracts, Vol. 94 (25), (1981), 208463b.							
	Koct (198	h, H.P., et al., "Thalic 5), pp. 165-242	domide and Conge	eners as A	Anti-inflammatory Agents	s", Progress i	n Medicinal Ct	hemistry, V	/ol. 22,
XAMINER					DATE CONSIDERED				
EXAMINER: In	nitial if reference	ce considered, whether his form with next comr	or not citation is in	conforma	ance with MPEP 609; Draw li	line through cit	ation if not in co	nformance	and not

Form PTO-A820 (also form PTO-1449) P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

į '		1129-178.111111 US	Application Number 10/622,618					
INFO	RMATION DISCLOSURE CITATION	Applicant(s)	10/022,010					
	(Us several sheets if necessary)	George W. Muller, et al.						
	() 300 \$	Filing Date July 17, 2003	Group Art Unit TBD					
*EXAMINER	OTHER DOCKSENTS (I.e. I.e. I.e.		TDD					
INITIAL	OTHER DOCOMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Ghassan S. Dbaibo, et al., "Tumor Necrosis Factor-alpha (TNF-alpha) Signal Transduction through Ceramide", The Journal of Biological Chemistry, Vol 268, No. 24, Aug. Issue, pp. 17762-17766 (1993)							
	Yuichiro J. Suzuki, et al., "Inhibition of NF-kB activation by vitamin E derivatives", Biochemical and Biophysical Research Communications, Vol. 193, No. 1, (May 1993), pp. 277-283							
	Guido Poli, et al., "The Effect of Cytokines and Pharmacologic Agents on Chronic HIV Infection", AIDS Research and Human Retroviruses, Vol. 8, No. 2, (1992), pp. 191-197							
	F. Bachelerie, et al., "HIV enhancer activity perpetuated by NF-kB induction on infection of monocytes", Letters to Nature, Vol. 350, (April 1991), pp. 709-712							
	S. Joseph Leibovich, et al., "Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha", Letters to Nature, Vol. 329, (Oct. 1987), pp. 630-632							
	Michael J. Lenardo, et al., "NF-kB: A Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control", Cell., Vol. 58, (July 1989), pp. 227-229							
	Kevin J. Tracey, et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin", Science, Vol. 234, pp. 470-474							
	L.B. Hinshaw, et al., "Survival of Primates in LD 100 Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNF-alpha)", Circulatory Shock, 30, (1990), pp. 279-292							
	L-M Ching, et al., "Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid", British Journal of Cancer, (1995), 72, pp. 339-343							
	N. B. Vedder, et al., "Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear", Proc. Natl. Acad. Sci. USA, Vol. 87 (April 1990), pp. 2643-2646							
	Thomas M. Folks, et al., "Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone", Proc. Natl., Acad. Sci. USA, Vol. 86, (April 1989), pp. 2365-2368							
	Kathleen A. Clouse, et al., "Monokine Regulation Human T Cell Clone", The Journal of Immunolog	of Human Immunodeficiency Virus- y, Vol. 142, No. 2, (Jan. 1989), pp. 43	1 Expression in a Chronically Infected 11-438					
EXAMINER		DATE CONSIDERED						
*EXAMINER: Initia	al if citation considered, whether or not citation is in conforms	ance with MPEP Section 609; Draw line t	hrough citation if not in conformance and					

•	***	Docket Number (Optional)	Application Number			
DIEGDIA	A TOTAL DATE OF A CONTRACT OF A TOTAL OF A CONTRACT OF A C	1129-178.111111 US	10/622,618			
INFORMA	ATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) George W. Muller, et al.				
QE 30		Filing Date July 17, 2003	Group Art Unit TBD			
CAMPINE 1	THER DOCUMENTS (Including Author, Titl	e, Date, Pertinent Pages, Etc.)				
INITIAL NIG						
PATEN	Katheen A. Clouse, et al., "Monokine Regulation of Monokine Regulation of Immunology	of Human Immunodeficiency Virus-1 v, Vol. 142, No. 2, (Jan. 1989), pp. 431	Expression in a Chronically Infected			
	Susan C. Wright, et al., "Spontaneous Cytotoxicity From AIDS Patients", The Journal of Immunology	and Tumor Necrosis Factor Product , Vol. 141, (July 1988), pp. 99-104	ion By Peripheral Blood Monocytes			
	John A. Lowe, III, et al., "The PDE IV family of ca (9), (1992), pp. 799-807	lcium-independent phosphodiesteras	e enzymes", Drugs of the Future, 17			
	Yuichiro J. Suzuki, et al., "Alpha-Lipoic acid is a p Biophysical Research Communications, Vol. 189, N	otent inhibitor of NF-kB activation in lo. 3, (1992), pp. 1709-1715	ı human T Cells", Biochemical and			
	E. Holler, et al., "Increased Serum Levels of Tumor Transplantation", Blood, Vol. 75, No. 4 (1990), pp.	r Necrosis Factor alpha Precede Majo 1011-1016	or Complications of Bone Marrow			
	Elyse Bissonnette, et al., "Pulmonary Inflammation of Tumor Necrosis Factor", Inflammation, Vol. 13,	and Fibrosis in a Murine Model of A No. 3, (1989), pp. 329-339	usbestosis and Silicosis - Possible Role			
	Elisabetta Ferrari-Baliviera, et al., "Tumor Necros Surg., Vol. 124, (Dec. 1989), pp. 1400-1405	is Factor Induces Adult Respiratory l	Distress Syndrome in Rats", Arch.			
	Georges E. Grau, et al., "Tumor Necrosis Factor an England Journal of Medicine, Vol. 320, No. 24, (Jun	nd Disease Severity in Children with 1 ne 1989), pp. 1586-1591	Falciparum Malaria'', The New			
	Pierre F. Piguet, et al., "Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis", Letters to Nature, Vol. 344, (Mar. 1990), pp. 245-247					
	Elia J. Duh, et al., "Tumor necrosis factor alpha ac nuclear factor binding to the NF-kB sites in the long 5974-5978	tivates human immunodeficiency viru g terminal repeat", Proc. Natl. Acad.	is type 1 through induction of Sci. USA, Vol. 86, (Aug. 1989), pp.			
	Donald R. Bertolini, et al., "Stimulation of bone res necrosis factors", Letters to Nature, Vol. 319, (Feb.	orption and inhibition of bone forma 1986), pp. 516-518	tion in vitro by human tumour			
	A. B. Millar, et al., "Tumour Necrosis Factor in Bro Syndrome", The Lancet, (Sept. 1989), pp. 712-714	onchopulmonary Secretions of Patien	ts with Adult Respiratory Distress			
XAMINER	I to the second	DATE CONSIDERED				
EXAMINER: Initial if	citation considered, whether or not citation is in conforma	ice with MPEP Section 609: Draw line the	rough citation if not in conformance and			

not considered. Include copy of this form with next communication to applicant.

			Docket Number (Optional)	Application Number			
			1129-178.111111 US	10/622,618			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			Applicant(s)				
			George W. Muller, et al.				
/0)	1 3 2003	Filing Date July 17, 2003	Group Art Unit TBD			
	100	13 200	July 17, 2003	180			
*EXAMINER OF ER DOCUMENTS (Including Authoritisal			tle, Date, Pertinent Pages, Etc.)				
	1	J. Michael Munro, et al., "Tumor Necrosis Factor Associated Leukocyte Accumulation in Skin of Papp. 121-133	and Interferon-y Induce Distinct Pat pio Anubis", American Journal of Pa	terns of Endothelial Activation and thology, Vol. 135, No. 1, (July 1989),			
		Didier Monte, et al., "Productive Human Immuno Tumor Necrosis Factor-alpha", Blood, Vol. 79, No	nunodeficiency Virus-1 Infection of Megakaryocytic Cells Is Enhanced by 9, No. 10, (May 1992), pp. 2670-2679				
		Hendrik M. Van Dullemen, et al., "Treatment of C Antibody (cA2)", Gastroenterology, Vol. 109 (1), (Crohn's Disease With Anti-Tumor Ne 1995), pp. 129-135	crosis Factor Chimeric Monoclonal			
	-	Alexander N. Shakhov, et al., "kB-Type Enhancer of the Tumor Necrosis Factor Alpha Gene in Prim	s Are Involved In Lipopolysaccharid ary Macrophages", J. Exp. Med., Vo	e-Mediated Transcriptional Activation l. 171, (Jan. 1990), pp. 35-47			
		Frank J. T. Staal, et al., "Intracellular thiols regul immunodeficiency virus", Proc. Natl. Acad. Sci. U	ate activation of nuclear factor kB ar SA, Vol. 87, (Dec. 1990), pp. 9943-99	nd transcription of human 47			
		R. A. Johnson, et al., "Tumors Producing Human Resorption in Nude Mice", Endocrinology, Vol. 12	Tumor Necrosis Factor Induce Hype 4, No. 3 (1989), pp. 1424-1427	rcalcemia and Osteoclastic Bone			
		Bruce J. Dezube, et al., "Pentoxifylline and wellbe	ing in patients with cancer", The Lar	cet, (Mar. 1990), pp. 662			
		Robert P. Baughman, et al., "Release of tumor nec Clin. Med., Vol. 115, No. 1, (Jan. 1990), pp. 36-42	crosis factor by alveolar macrophages	s of patients with sarcoidosis", J. Lab.			
Debajit K. Biswas, et al., "Pentoxifylline Inhi of Acquired Immune Deficiency Syndromes,			HIV-1 LTR-Driven Gene Expression 6, No. 7, (1993), pp. 778-786	by Blocking NF-kB Action", Journal			
Louis J. Lombardo, "Phosphodiesterase-IV I Current Pharmaceutical Design, Vol. 1, No. 2			tors: Novel Therapeutics for the Tre 95), pp. 255-268	atment of Inflammatory Diseases",			
		Barbara Sherry, et al., "Cachectin/Tumor Necrosi Inflammatory Responses", The Journal of Cell Bio	s Factor Exerts Endocrine, Paracrino Dlogy, Vol. 107, (1988), pp. 1269-1277	e, and Autocrine Control of			
	M. J. Elliott, et al., "TNF-alpha Blockade in Rheumatoid Arthritis: Rationale, Clinical Outcomes and Mechanisms of Action", Int. J. Immunopharmac., Vol. 17, No. 2, (1995), pp. 141-145						
EXAMINER			DATE CONSIDERED				
		citation considered, whether or not citation is in conformation to applicant.	ance with MPEP Section 609; Draw line the	nrough citation if not in conformance and			

•		-	Docket Number (Optional)	Application Number	
INEC	DRMA	ATION DISCLOSURE CITATION	1129-178.111111 US Applicant(s)	10/622,618	
DE	1C83	Use several sheets if necessary)	George W. Muller, et al.		
/\ <u>`</u>	Ennc	4	Filing Date July 17, 2003	Group Art Unit TBD	
*EXAMINER \		OTHER DOCUMENTS (Including Author, Title	le, Date, Pertinent Pages, Etc.)		
.	RAT	Zeda F. Rosenberg, et al., "The Immunopathogene 377-431	esis of HIV Infection", Advances in I	nmunology, Vol. 47, (1989), pp.	
		Laurelee Osborn, et al., "Tumor necrosis factor all enhancer by activation of the nuclear factor kB", f	pha and interleukin 1 stimulate the h Proc. Natl. Acad. Sci. USA, Vol. 86, (A	uman immunodeficiency virus April 1989), pp. 2336-2340	
		Guido Poli, et al., "Tumor necrosis factor alpha fui immunodeficiency virus expression", Proc. Natl. A	nctions in an autocrine manner in th cad. Sci. USA, Vol. 87, (Jan. 1990), p	e induction of human p. 782-785	
		Yuichiro J. Suzuki, et al., "Inhibitin of NF-kB DNA Molecular Biology International, Vol. 31, No. 4, (N	A Binding Activity By alpha-tocophe ov. 1993), pp. 693-700	ryl Succinate", Biochemistry and	
		Kevin J. Tracey, et al., "Anti-cachectin/TNF monocto Nature, Vol. 330, (Dec. 1987), pp. 662-664	clonal antibodies prevent septic shoc	k during lethal bacteraemia", Letters	
, — II		Gregory R. Mundy, "Incidence and Pathophysiolog	gy of Hypercalcemia", Calcif Tissue	Int., [Suppl], 46, (1990), pp. S3-S10	
		•			
EXAMINER			DATE CONSIDERED		
EXAMINER: Ini	tial if c	itation considered, whether or not citation is in conforma	ngo with MDFD Section 600, Drew line 4h	manual alded and for addition of the same	

not considered. Include copy of this form with next communication to applicant.